Maa: Irlanti
Kieli: englanti
Lähde: HPRA (Health Products Regulatory Authority)
AZITHROMYCIN DIHYDRATE
Pfizer Limited
600 Milligram
Film Coated Tablet
1997-07-11
IRISH MEDICINES BOARD ACT 1995, AS AMENDED MEDICINAL PRODUCTS (CONTROL OF PLACING ON THE MARKET) REGULATIONS, 2007, AS AMENDED PA0019/047/010 Case No: 2075523 The Irish Medicines Board in exercise of the powers conferred on it by the above mentioned Regulations hereby grants to PFIZER LIMITED RAMSGATE ROAD, SANDWICH, KENT CT13 9NJ, UNITED KINGDOM an authorisation, subject to the provisions of the said Regulations, in respect of the product ZITHROMAX 600MG TABLETS the particulars of which are set out in the attached Schedule. The authorisation is also subject to the general conditions as may be specified in the said Regulations as listed on the reverse of this document. This authorisation, unless previously revoked, shall continue in force from 07/07/2010. Signed on behalf of the Irish Medicines Board this ________________ A person authorised in that behalf by the said Board. IRISH MEDICINES BOARD ________________________________________________________________________________________________________________________ _Date Printed 07/07/2010_ _CRN 2075523_ _page number: 1_ PART II SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Zithromax 600mg Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains azithromycin dihydrate equivalent to 600 mg azithromycin. Excipients: also includes lactose monohydrate, up to 43.2mg per tablet. For a full list of exipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet. (Tablet) White, capsular shaped, film-coated tablets marked “Pfizer” on one side and “ZTM 600” on the other. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Zithromax is indicated, either alone or in combination with rifabutin, for prophylaxis against Mycobacterium avium- intracellulare complex (MAC) infection, an opportunistic infection prevalent in patie Lue koko asiakirja